Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review
Mental Health Clinician · 01.11.2016 · 6 (6) · 308-313
DOI: 10.9740/mhc.2016.11.308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mental Health Clinician, erschienen am 01.11.2016. Verfasst von Chelsea N Carr und 3 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatric Clinical Pharmacy Specialist, Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania, clarkc237@gmail.com. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Quetiapine fumarate is an atypical antipsychotic approved for the treatment of schizophrenia, major depressive disorder, and bipolar disorder. Due to the sedative effects observed at low doses, prescribers use quetiapine to aid patients with sleep disturbances. Current evidence has established that quetiapine can cause negative changes in metabolic parameters, but it is unknown if these consequences also occur at low doses. Due to the use of quetiapine for sleep, the purpose of this study is to identify if metabolic effects are also a risk with the use of low-dose quetiapine.
Methods
Eligible subjects were identified through the Veterans Affairs electronic medical records as having an active prescription for quetiapine from June 30, 2012, through September 1, 2013. Subjects were then evaluated using inclusion and exclusion criteria for determination of study entrance. Descriptive statistics and t tests were utilized to identify clinical and statistical differences in outcomes.
Results
A total of 403 subjects were included in the final analysis. The average dose of quetiapine was 116.8 mg and average duration of therapy was 44 months. Increases were observed in systolic blood pressure (+1.95 mmHg; P = .036), diastolic blood pressure (+1.97 mmHg; P = .001), body mass index (+0.52; P = .001), weight (+1.88 kg; P = .002), and fasting blood glucose (+6.71 mg/dL; P = .002). Conversely, a decrease in total cholesterol (−10.06 mg/dL; P < .001) was recognized.
Discussion
As a result of the findings, there may be negative metabolic consequences with the use of low-dose quetiapine. Routine prescribing of low doses for sleep as a first-line medication should be avoided.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Psychiatric Clinical Pharmacy Specialist, Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania, clarkc237@gmail.com.
- Clinical Pharmacy Specialist, Sharp Mesa Vista Hospital, San Diego, California; Voluntary Clinical Instructor, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California; Adjunct Clinical…
- Clinical Pharmacy Specialist, Battle Creek Veteran Affairs Medical Center, Battle Creek, Michigan.
Zitieren
APA
Carr, C. N., Lopchuk, S., Beckman, M. E., & Baugh, T. B. (2016). Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review. Mental Health Clinician, 6(6), 308-313. https://doi.org/10.9740/mhc.2016.11.308
Vancouver
Carr CN, Lopchuk S, Beckman ME, Baugh TB. Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review. Mental Health Clinician. 2016;6(6):308-313. doi:10.9740/mhc.2016.11.308
BibTeX
@article{Carr2016,
author = {Carr, Chelsea N and Lopchuk, Shruti and Beckman, Mary E and Baugh, Terrence Bradley},
title = {Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review},
journal = {Mental Health Clinician},
year = {2016},
volume = {6},
number = {6},
pages = {308--313},
doi = {10.9740/mhc.2016.11.308}
}
EUVIMED